Freezing tumors may boost immunotherapy in advanced lung cancer: new trial

NCT ID NCT04339218

Recruiting now Disease control Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

First seen Jan 31, 2026 · Last updated Jun 17, 2026 · Updated 18 times

Summary

This study tests whether freezing a tumor (cryoablation) plus standard immunotherapy and chemotherapy helps people with advanced lung cancer live longer. About 214 participants will be randomly assigned to receive either the standard drug combination alone or with the freezing treatment. The main goal is to see if adding cryoablation improves survival at one year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Institut Bergonié
RECRUITING

Bordeaux, Gironde, 33076, France

Contact Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRYOTHERAPY EFFECT LUNG ADENOCARCINOMA